Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non–ST-segment elevation acute coronary syndromes patients: An analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome trial-Reference-Cited by-同舟云学术

Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non–ST-segment elevation acute coronary syndromes patients: An analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome trial

Published:2013-09 Issue:3 Volume:166 Page:466-473.e1
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Bagai Akshay,White Jennifer A.,Lokhnygina Yuliya,Giugliano Robert P.,Van de Werf Frans,Montalescot Gilles,Armstrong Paul W.,Tricoci Pierluigi,Gibson C. Michael,Califf Robert M.,Harrington Robert A.,Newby L. Kristin

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference17 articles.

1. Early versus delayed, provisional eptifibatide in acute coronary syndromes;Giugliano;N Engl J Med,2009

2. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators;Kleiman;Circulation,2000

3. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy;Roffi;Eur Heart J,2002

4. Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods;Pieper;Circulation,2004

5. The Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non–ST-segment elevation acute coronary syndrome—Study design and rationale

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiplatelet agents for chronic kidney disease;Cochrane Database of Systematic Reviews;2022-02-28

2. Safety and Effectiveness of Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis;Frontiers in Pharmacology;2017-07-11